Cardiology Update 2013

Scientific Programme

Monday, 11 February 2013

Atherosclerosis, Hypertenison, Diabetes

Room Davos 2

08:00-08:15 Opening and Welcome Address
T.F. Lüscher, Zurich

• Opening Address by the President of the ESC
  P. Vardas, Heraklion

08:15-09:00 Paul Lichtlen Lecture
Personalised cardiovascular medicine and drug development: Time for a new paradigm
J. Loscalzo, Boston

09:00-10:00 Morning Session 1: Atherosclerosis
Chair: F. Crea, Rome and B. Pitt, Ann Arbor

• 09:00 Inflammation and atherosclerosis: an update 
  P. Libby, Boston
• 09:30 Lifetime risk: Are current risk scores short sighted?
  J. Deanfield, London

10:00-11:30 Morning Session 2: Hypertension
Chair: F. Messerli, New York and D. Wood, London

• 10:00 The emerging controversy of salt and CVD 
  S. Yusuf, Hamilton
• 10:22 Impact of target damage in the management of hypertension: endothelium, the heart and the kidney
  S. Taddei, Pisa
• 10:44 State-of-the art treatment of hypertension: established and new drugs
  M. Burnier, Lausanne
• 11:06 Renal denervation for resistant hypertension 
  T.F. Lüscher, Zurich

Room Schwarzhorn
Update Hypertension Medical Treatment
Chair : G. Noll, Zurich

• 12:00 Introduction
  G. Noll, Zurich
• Challenges in Hypertension: is combination the answer? 
  M. Burnier, Lausanne
• 12:25 Hypertension: Hot topics 2013
  G. Predel, Köln
• 12:45 How to win a Nobel Prize
  F. Messerli, New York
• 13:05 Discussion and conclusion
  G. Noll, Zurich

Room Davos 2
13:30-15:00 Afternoon Session 1: Prevention, Diabetes and Renal Disease
Chair: D. Milicic, Zagreb and P. Vardas, Heraklion

• 13:30 The new ESC Guidelines on Cardiovascular Prevention 
  D. Wood, London
• 13:52 Update on cardiovascular outcome trials in diabetes 
  R. Holman, Oxford
• 14:14 Cholesterol lowering in kidney disease and/or diabetes: Is it safe and efficient? 
  C. Baigent, Oxford
• 14:36 Why is antidiabetic treatment less effective than expected? 
  F. Cosentino, Rome

Risk Factors, Hypertension, Diabetes
15:30-16:30 Meet the Expert Sessions / Live in-a-Box(Parallel Sessions)

• Schwarzhorn Managing global and life time risk
  Experts: J. Deanfield, London and D. Wood; London
  Cases: R. Erbel; Essen and J. Ghadri, Zurich
• Seehorn Hypertension and diabetes: Case based management
  Experts: R. Holman, Oxford and P. Sleight, Oxford
  Cases: A. Breitenstein, Zurich and S. Taddei, Pisa
• Wisshorn Live in-a-Box: Renal denervation
  Selecting the right patient
  I. Sudano, Zurich
  How to perform the procedure 
  G. Noll, Zurich

Foyer
15:30-16:30 Poster Session: Atherosclerosis, Cardiovascular Risk Factors 
Chair: T. Gillebert, Ghent

Room Davos 2
16:30-17:30 Afternoon Session 2: How can we better translate evidence into practice?
Chair: C. Baigent, Oxford and G. Noll, Zurich

• 16:30 Lifestyle modification
  D. Wood, London
• 16:50 Secondary prevention: The ELIPSE trial and beyond
  F. Mach, Geneva
• 17:10 Gaps in hypertension detection, treatment and control: How can we improve?
  S. Yusuf, Hamilton

Anticoagulation, Iron Deficiency, Echo

Room Davos 2
18:00-19:15 Satellite Symposium Bayer Healthcare
Selective FXa Inhibition with Rivaroxaban: Current Indications and Future Perspectives
Chair: T.F. Lüscher, Zurich

• 18:00 Introduction 
  T.F. Lüscher, Zurich
• 18:10 Cardiovascular effects and profile of Rivaroxaban
  S. Heitmeier, Wuppertal
• 18:30 Dosing across indications
  H. Rickli, St. Gallen
• 18:50 Practical experience in the cardiology setting
  B. Meier, Bern
• 19:10  Discussion
  T.F. Lüscher, Zurich

Room Davos 1
18:00-19:15 Satellite Symposium Vifor Pharma
Iron Deficiency in Heart Failure – from Evidence to Practice
Chair: M. Böhm, Homburg/Saar and G. Noll, Zurich

• 18:00 Chair’s introduction 
  G. Noll, Zurich
• 18:10 The iron link in the vicious circle of heart failure 
  P. van der Meer, Groningen
• 18:25 Iron deficiency – new therapeutic target in heart failure
  S. Anker, Berlin
• 18:40 My patient is iron deficient: what’s next ?
  O. Pfister, Basel
• 18:55 Q & A Session
  M. Böhm, Homburg/Saar

Room Schwarzhorn
19:20-20:15 Clinical Decision Seminar
Pearls of Echocardiography
Panel and Cases: P. Biaggi, Zurich, T. Gillebert, Ghent, D. Milicic, Zagreb and F.C. Tanner, Zurich

Tuesday, 12 February 2013

Dyslipidemia, CAD

Room Davos 2
08:00-09:30 Morning Session 1: Lipids: Current Practice and Future Targets
Chair: C. Matter, Zurich and P. Libby, Boston

• 08:00 Practical approaches to managing patients with dyslipidemia – The new ESC/EAS guidelines and beyond
  J. Chapman, Paris
• 08:22 Statins in primary prevention
  C. Baigent, Oxford
• 08:44 HDL-dysfunction and CETP inhibition
  U. Landmesser, Zurich
• 09:06 Inhibition of PCSK9 - a new approach to lower LDL
  J.J.P. Kastelein, Amsterdam

10:00-11:30 Morning Session 2: Prevention and Coronary Artery Disease
Chair: J.J.P. Kastelein, Amsterdam and J. Perk, Kalmar

• 10:00 Heart rate: a new risk factor for CAD and HF
  R. Ferrari, Ferrara
• 10:22 Coronary microvascular dysfunction
  F. Crea, Rome
• 10:44 Protective effect of coronary collateral circulation
  C. Seiler, Bern
• 11:06 Progression of coronary artery calcification: risk and risk factors
  R. Erbel, Essen

Room Schwarzhorn
12:00-13:15 Satellite Symposium MSD, Merck Sharp & Dohme
Managing Patients with Dyslipidemia: Clinical Considerations and Practical Approaches
Chair: J. Deanfield, London and F. Mach, Geneva

• 12:00 Introduction
  F. Mach, Geneva
• 12:05 LDL-C and residual risk: Rationale for using combination therapy in lipid management strategies
  F. Mach, Geneva
• 12:25 Protecting the heart and the kidney: Implications from the SHARP Trial 
  C. Baigent, Oxford
• 12:45 HDL-C and residual risk: lipid management in patients with metabolic disease and overt residual risk
  J. Kastelein, Amsterdam
• 13:05 Discussion and conclusion
  J. Deanfield, London

Room Davos 2
13:30-15:00 Afternoon Session 1A: Cardiovascular Trials Update
Chair: W. Maier, Zurich and P. Sleight, Oxford

• 13:30 RELAX AHF: Potential of paradigm shifting in acute heart failure?
  P. Ponikowski, Wroclaw
• 13:50 : Discussant
  F. Ruschitzka, Zurich
• 14:00 Woest Study: Optimal antiplatelet and anticoagulant therapy in patients with anticoagulation and coronary stenting
  J. Ten Berg, Nieuwegein
• 14:20: Discussant 
  J. Steffel, Zurich
• 14:30 Swiss AMI Study: What can we achieve with stem cells?
  D. Sürder, Lugano
• 14:50 Discussant 
  A. Zeiher, Frankfurt

Thrombosis, Sports Cardiology, GUCH

Room Davos 1
13:30-15:00 Afternoon Session 1B: Thrombosis and Pulmonary Embolism
Chair: A.J. Camm, London and S. Yusuf, Hamilton

• 13:30 Intermediate-risk pulmonary embolism: What does it mean in clinical practice?
  S. Konstantinides, Mainz
• 14:00 Ultrasound-assisted thrombolysis for acute PE
  N. Kucher, Bern
• 14:14Single drug approach for anticoagulation of acute PE – the EINSTEIN PE –Trial 
  S. Schellong, Dresden
• 14:36 Implications from the ACCP 2012 Consensus Guidelines for the Management of Thrombosis:a case based approach 
  I. Baumgartner, Bern

15:30-16:30 Meet the Expert Sessions / Live in-a-Box(Parallel Sessions)

• Schwarzhorn Lipid management
  Experts: J. Chapman, Paris, J. Kastelein, Amsterdam and J. Perk, Kalmar
  Cases: D. Schmidt, Zurich and I. Sudano Zurich
• Seehorn Sports cardiology
  Experts: C. Schmied, Zurich and D. Corrado, Padova
  Cases: M. Borjesson, Stockholm and A. Brauchlin, Zurich
• Wisshorn Live in-a-Box: Practical assessment of coronary lesions: FFR and OCT
  • FRR – how it works
    C. Seiler, Bern
  • FFR – practical demonstration
    Ch. Wyss, Zurich
  • OCT – how it works
    U. Landmesser, Zurich
  • OCT – practical demonstration 
    M. Jaguszewski, Zurich

Foyer
15:30-16:30 Poster Session: Angina, Acute Coronary Syndromes, Revascularisation
Chair: G. Pitt, Durham

Room Davos 2
16:30-17:30 Afternoon Session 2A: Sports Cardiology
Chair: F. Mach, Geneva and S. Taddei, Pisa

• 16:30 Sudden cardiac death in sports: Causes and current screening recommendations
  D. Corrado, Padova
• 16:50 Recommendations for sports participation in patients with known cardiovascular disease
  C. Schmied, Zurich
• 17:10 BLS/AED and rescue on the pitch: time to react 
  M. Borjesson, Stockholm

Room Davos 1
16:30-17:30 Afternoon Session 2B: GUCH
Chair: L. Eckardt, Münster and I. Lang, Vienna

• 16:30 What’s new in congenital heart disease? 
  J.E. Deanfield, London
• 16:50 Congenital heart disease and pregnancy 
  M. Greutmann, Zurich
• 17:10 Eisenmenger’s syndrome – a call for action
  M. Gatzoulis, London

Anticoagulation, Dyslipidemia, Imaging, CRT

Room Davos 2
18:00-19:15 Satellite Symposium Boehringer Ingelheim
Stroke Prevention in Patients with Atrial Fibrillation – Different Perspectives and Practical Approaches
Chair: A.J. Camm, London and T.F. Lüscher, Zurich

• 18:00 Introduction – Dabigatran use on the long termT.F. Lüscher, Zurich
• 18:20 Treatment recommendations in non valvular atrial fibrillation 
  A.J. Camm, London
• 18:45 Practical cases and experience
  G. Noll, Zurich
• 19:05 Q&A session
  all

Room Davos 1
18:00-19:15 Satellite Symposium Eli Lilly
Management of Dyslipidemias: What is New on the Horizon?
Chair: F. Mach, Geneva

• 18:00 Introduction 
  F. Mach, Geneva
• 18:05 Clinical benefits of statin therapy: L DL-lowering and/or anti-inflammatory?
  P. Libby, Boston
• 18:25 The new ESC guidelines on cardiovascular disease prevention
   J. Perk, Kalmar (SE)
• 18:45 Pitavastatin: what can be we expect from a new statin? 
  M.J. Chapman, Paris
• 19:05 Discussion and conclusion
  F. Mach, Geneva

19:20-20:15 Clinical Decision Seminars (parallel Sessions)

• Schwarzhorn - Imaging
  Panel and Cases: J.J. Bax, Leiden, P.G. Camici, Milan, O. Gämperli, Zurich and R. Manka, Zurich
• Seehorn - CRT and ICD Trouble Shooting
  A new APP for iPhone and iPad
  D. Hürlimann, Zurich and J. Steffel, Zurich

Wednesday, 13 February 2013

Atrial Fibrillation, Cardiomyopathies, CRT, Antiplatelets

Room Davos 2
08:00-09:30 Morning Session 1: Atrial Fibrillation
Chair: C. Brunckhorst, Zurich and G. Hindricks, Leipzig

• 08:00 AF: milestones achieved and future perspectives
  A.J. Camm, London
• 08:22 Bringing the new EHRA/HRS guidelines to daily clinical practice 
  H. Calkins, Baltimore
• 08:44 Medical management of AF
  L. Eckardt, Münster
• 09:06  Catheter ablation of AF
  L. Haegeli, Zurich

Room Davos 2
10:00-11:30 Morning Session 2: Cardiomyopathies, Sudden Death
Chair: F. Duru, Zurich and H. Calkins, Baltimore

• 10:00 Prevention of sudden cardiac death
  G. Hindricks, Leipzig
• 10:22 Sudden cardiac death in hypertrophic cardiomyopathy: risk stratification and the role of molecular genetics
  C. Gruner, Zurich
• 10:44 Arrhythmogenic right ventricular cardiomyopathy: State of the art
  H. Calkins, Baltimore
• 11:06 Takotsubo cardiomyopathy
  J. Ghadri, Zurich

Room Schwarzhorn
12:00-13:15 Satellite Symposium Biotronik
Cardiac Resynchronisation Therapy for Chronic Heart Failure - What’s New?
Chair: J. Holzmeister, Zurich

• 12:00 Introduction
  J. Holzmeister, Zurich
• 12:05 Evolving indications for cardiac resynchronization therapy: A transatlantic consensus
  W.T. Abraham, Cincinnati
• 12:25 CRT optimisation – a modern, integrative approach 
  J. Steffel, Zurich
• 12:45 CRT and MRI – novel advances 
  D. Hürlimann, Zurich
• 13:05 Discussion and conclusion
  J. Holzmeister, Zurich

Room Seehorn
12:00-13:15 Satellite Symposium Daiichi Sankyo and Eli Lilly
Myth and Reality with Antiplatelet Therapy
Chair: F. Mach, Geneva

• 12:00 Introduction
  F. Mach, Geneva
• 12:05  Dual antiplatelet therapy in ACS/PCI: Current recommendations and corresponding data
  B. Meier, Berne
• 12:25 Myth and reality with antiplatelet therapy 
  G. Montalescot, Paris
• 12:45 Experience with Prasugrel in daily practice: case reports
  R. Corti, Zurich
• 13:05 Discussion and conclusion
  F. Mach, Geneva

Imaging, Personalised Medicine, Pulmonary Hypertension

Room Davos 2
13:30-15:00  Afternoon Session 1B: Imaging
Chair: P.G. Camici, Milan and F.C. Tanner, Zurich

• 13:30 The vulnerable plaque: the pathologist’s view 
  R. Virmani, Gaithersburg MD
• 13:52 Plaque imaging: the new frontier
  P.G. Camici, Milan
• 14:14 CT coronary angiography and perfusion imaging: alone or in combination? 
  O. Gämperli, Zurich
• 14:36 Differential imaging: What do we need for which patient? 
  J.J. Bax, Leiden

Room Davos 1
13:30-15:00 Afternoon Session 1A: Personalised Medicine – Hype or Hope?
Chair: S. Dimmeler, Frankfurt and M.L. Simoons, Rotterdam

• 13:30 Genetics and personalised medicine for CAD 
   H. Schunkert, Munic
• 13:55 Genetics of cardiovascular diseases: new frontiers for diagnosis, risk stratification and therapy
  G. Pitt, Durham N
• 14:20 Personalised medicine: Can we use clinical and routine laboratory data better?
  F.L.J. Visseren, Utrecht
• 14:45 Discussion

15:30-16:30 Meet the Expert Sessions / Live in-a-Box
(Parallel Sessions)

• Schwarzhorn How to reduce stroke risk in AF?
  Experts: A.J. Camm, London and J. Steffel; Zurich
  Cases: N. Krasniqi, Zurich and N. Kucher, Bern
• SeehornCardiomyopathies, sudden death:
  Experts: H. Calkins, Baltimore and G. Hindricks; Leipzig
  Cases: C. Gruner, Zurich and A. Saguner, Zurich
• Wisshorn Live in-a-Box: Atrial fibrillation
  • Indications
    C. Brunckhorst, Zurich
  • How to perform AF ablation
    L. Haegeli, Zurich

Room Davos 2
16:30-17:30 Afternoon Session 2A: Pulmonary Hypertension
Chair: T. Gillebert, Ghent and R. Speich, Zurich

• 16:30  Screening and diagnosing PH – still a challenge
  I. Lang, Vienna
• 16:50 Current therapeutic approaches and expected update in the guidelines
  M. Palazzini, Bologna
• 17:10 Chronic thromboembolic pulmonary hypertension 
  E. Mayer, Bad Nauheim

Stem Cells, Anticoagulation, Heart Failure, ECG

Room Davos 1
16:30-17:30 Afternoon Session 2B: Stem Cells
Chair: U. Landmesser, Zurich and G. Pitt, Durham NC

• 16:30 MicroRNAs: novel therapeutics and diagnostics in cardiovascular disease
  S. Dimmeler, Frankfurt
• 16:50 Cell therapy in STEMI: closing the clinical gap 
  A. Zeiher, Frankfurt
• 17:10 Update on induced pluripotent stem cells for the treatment of ischemic cardiomyopathy 
  U. Martin, Hannover

Room Davos 2
18:00-19:15 Satellite Symposium Daiichi Sankyo
The New Aerea of Anticoagulation – Achievements and Challenges
Chair: T.F. Lüscher, Zurich

• 18:00 Introduction
  T.F. Lüscher, Zurich
• 18:10 Modern concept of NOACs – opportunities and challenges
  W. Korte, St. Gallen
• 18:25 Edoxaban – from bench to clinical trials 
  J. Steffel, Zurich
• 18:40 Engage AF-Timi 48 – Edoxaban in AF: What can we expect? 
  A.J. Camm, London
• 18:55  Hokusai VTE – Edoxaban in VTE: What can we expect?
  S.M. Schellong, Dresden
• 19:10 Discussion and conclusion
  T.F. Lüscher, Zurich

Room Davos 1
18:00-19:15 Satellite Symposium Novartis
A Novel First in Class Treatment in Acute Heart Failure:Late Stage Development Project
Chair: P. Mohacsi, Bern

• 18:05 The economic burden of heart failure
  T.D. Szuccs, Basel
• 18:25 Novel treatment option in acute heart failure: What is serelaxin?
  R.A. Rocha, Basel
• 18:45 What serelaxin promises: the RELAX-AHF data 
  P. Ponikowski, Wroclaw
• 19:05 Discussion
  P. Mohacsi, Bern

Room Schwarzhorn
19:20-20:15 Clinical Decision Seminar
The challenging ECG
Panel and cases: C. Brunckhorst, Zurich, F. Duru, Zurich and L. Eckardt, Münster

Thursday, 14 February 2013

ACS, Percutaneous Interventions, Ischemic Heart Disease

Room Davos 2
08:00-09:30 Morning Session 1: Acute Coronary Syndromes
Chair: T.F. Lüscher, Zurich and W. Wijns, Aalst

• 08:00 Case presentation: Decision making in ACS 
  O. Gämperli, Zurich
• 08:10 Biomarkers and ACS
  C. Müller, Basel
• 08:30 Decision making in ACS: The new ESC Guidelines in STEMI 
  S.K. James, Uppsala
• 08:50 ESC NSTEMI Guidelines: an update
  C. Hamm, Bad Nauheim
• 09:10 Stent choice in patients with acute MI
  S. Windecker, Bern

Room Davos 2
10:00-11:30 Morning Session 2: Percutaneous Interventions
Chair: B. Meier, Bern and T. Moccetti, Lugano

• 10:00  Case presentation: Decision making in three vessel disease 
  G. Pedrazzini, Lugano
• 10:22  Invasive coronary diagnostics: research tools or clinically relevant? 
  W. Wijns, Aalst
• 10:44  How to treat multivessel disease in STEMI patients?
  P. Widimsky, Prague
• 11:06 Revised definitions of MI, implications for clinical trials 
  M.L. Simoons, Rotterdam

Room Davos 1
11:45-13:00  Satellite Symposium A. Menarini
Management of Ischemic Heart Disease – Special Focus on Patients with Diabetes Mellitus
Chairperson: G. Noll, Zurich

• 11:45 Introduction 
  G. Noll, Zurich
• 11:50 Pathophysiology of ischemic heart disease –  focus on patients with diabetes mellitus 
  D. Westermann, Berlin
• 12:10 Clinical challenges in diabetic patients with coronary    heart disease – an interactive patient case discussion 
  G. Noll, Zurich
• 12:30  How to successfully manage patients with ischemic heart disease 
   F. Mach, Geneva
• 12:50 Q & A, discussion 
  all

Stents, Antiplatelets, Heart Failure, Aortic Valve, Cardiovascular Care

Room Seehorn
13:15-14:30 Satellite Symposium AstraZeneca with Biosensors
New Stents and Antiplatelets: Is it Time to Say Goodbye to Aspirin?
Chairperson: H. Schunkert, Munich

• 13:15 Introduction 
  H. Schunkert, Munich
• 13:20  New stent developments: 5 years of experience  (LEADERS, COMFORTABLE AMI)
  T.F. Lüscher, Zurich
• 13:40 Ticagrelor – platelet inhibition and beyond 
  C.W. Hamm, Bad Nauheim
• 14:00  Dual vs. single antiplatelet therapy – the GLOBAL LEADERS Study 
  S. Windecker, Bern
• 14:20 Discussion and conclusion 
  H. Schunkert, Munich

Room Schwarzhorn
13:15-14:30 Satellite Symposium Cardiorentis
Therapy for Acute Heart Failure – Time for Change?!
Chair: S. Anker, Berlin

• 13:15  Introduction 
  S. Anker, Berlin
• 13:20 ESC Guidelines for the treatment of acute heart failure 
  P. Ponikowski, Wroclaw
• 13:40 Why to treat acute heart failure early -   Similarities to the acute coronary syndrome 
  A. Mebazaa, Paris
• 14:00 The TRUE-AHF programme – Ularitide in patients with acute heart failure 
  G. Filippatos, Athens
• 14:20 Panel discussion 
  all

Room Davos 2
14:30-16:00 Afternoon Session 1A: Aortic Valve Disease
Chair: R. Corti, Zurich and P. Widimsky, Prague

• 14:30  Imaging to select and guide transcatheter aortic  valve implantation (TAVI)  
   J.J. Bax, Leiden
• 14:52 ESC/EACTS Guidelines on valve disease 
  A. Vahanian, Paris
• 15:14 TAVI: transapical procedures 
  V. Falk, Zurich
• 15:36 Randomised trials comparing TAVI with SAVR
  S. Windecker, Berne

Room Davos 1
14:30-16:00  Afternoon Session 1B: Special Topics of Cardiovascular Care
Chair: C. Hamm, Bad Nauheim and H. Schunkert, Munich

• 14:30 Catheter-based LAA occlusion: promising experiences 
  U. Landmesser, Zurich
• 14:52 Patent foramen ovale: Update 
  B. Meier, Bern
• 15:14 HIV and cardiovascular disease
  H.C. Bucher, Basel
• 15:36  Treatment of perioperative myocardial infarction: Tightrope walk between thrombosis and bleeding  
  H. Rickli, St. Gallen

Percutaneous Interventions, Mitral Valve

16:15-17:00 Meet the Expert Sessions / Live in-a-Box (Parallel Sessions)

• Schwarzhorn Management of CAD: Drugs, PCI or CABG?
  Experts: V. Falk, Zurich, M.L. Simoons, Rotterdam and S. Windecker, Berne
  Cases: O. Gämperli, Zurich and C. Wyss, Zurich
• Seehorn   Optimal management of STEMI
  Experts: S.K. James, Uppsala and P. Widimsky, Prague
  Cases: C. Matter, Zurich and D. Sürder, Lugano
• Wisshorn   Live in-a-box: Left Atrial Appendix Occlusion
  • How to select patients 
     J. Steffel, Zuri
  • The LAA occlusion procedure 
    U. Landmesser, Zurich

Room Davos 2
17:00-18:30 Afternoon Session 2: Mitral Valve Regurgitation
Chair: J.J. Bax, Leiden and A. Vahanian, Paris

• 17:00  Anatomy and pathology of the mitral valve 
  R. Virmani, Gaithersburg, MD
• 17:20  Management of mitral regurgitation 
  A. Vahanian, Paris
• 17:40 Minimally invasive mitral valve surgery – standard of care
  V. Falk, Zurich
• 18:00 Percutaneous mitral valve treatment
  R. Corti, Zurich
• 18:20 Poster Award 
  T.F. Lüscher, Zurich

Friday, 15 February 2013

Heart Failure

Room Davos 2
08:00-09:30 Morning Session 1: Chronic Heart Failure
Chair: M. Gheorghiade, Chicago and F. Ruschitzka, Zurich

• 08:00 ESC/HFA Guidelines on HF: update 
  S. Anker, Berlin
• 08:22  How the imager can help the heart failure doctor in diagnosis and treatment 
  J.J. Bax, Leiden
• 08:44  HF with preserved ejection fraction: epidemiology and management 
  K. Swedberg, Gothenborg
• 09:06 The right heart: the cinderella of heart failure 
  P. Ponikowski, Wroclaw

Room Davos 2
10:00-11:30  Morning Session 2: Treatment of Heart Failure
Chair: S. Anker, Berlin and K. Swedberg, Gothenborg

• 10:00 Novel drugs in acute HF 
  M. Gheorghiade, Chicago
• 10:25 Mineralcorticoid receptor blockade in CV disease: potential new indications and new drugs 
  B. Pitt, Ann Arbor MI
• 10:50 Therapeutic value of renin inhibitors 
  M. Pfeffer, Boston
• 11:15 Discussion

Room Davos 2
11:45-13:00  Lunch Session: Devices in Heart Failure
Chair: M. Pfeffer, Boston and P. Ponikowski, Wroclaw

• 11:45  How to assess dyssynchrony? 
  O.A. Smiseth, Oslo
• 12:10  CRT in heart failure: new frontiers 
  D. Gras, Nantes
• 12:35 Patient selection for CRT 
  D. Hürlimann, Zurich

Heart Failure, Transplantation

13:15-14:15 Meet the Expert Sessions / Live in-a-Box (Parallel Sessions)

• Schwarzhorm-Managing advanced heart failure
  Experts: F. Ruschitzka, Zurich and P. Ponikowski, Wroclaw
  Cases: F. Enseleit, Zurich and A. Rudiger, Zurich
• Seehorn -  Managing complex systolic heart failure patients
  Experts: G. Noll, Zurich and O.A. Smiseth, Oslo
  Cases: A. Flammer, Zurich and D. Hürlimann, Zurich
• Wisshorn -  Live in-a-box: Transcatheter aortic valve implantation (TAVI)
  Moderator / A. Vahanian, Paris
  • Results of TAVI: The Zurich experience / B. Stähli, Zurich
  • How to perform the procedure / R. Corti, Zurich

Room Davos 2
14:30-15:45 Afternoon Session: From Heart Failure to Transplantation
Chair: B. Pitt, Ann Arbor and O.A. Smiseth, Oslo

• 14:30 Advanced heart failure
  F. Ruschitzka, Zurich
• 14:55 Novel devices for HF 
  P. Ponikowski, Wroclow
• 15:20 Mechanical assist devices: from bridge to transplant to destination therapy
  V. Falk, Zurich

15:45-16:15 Davos Lecture
Stem cells in cardiovascular disease: myth or reality?
A. Zeiher, Frankfurt

16:15 Closing Remarks
B. Pitt, Ann Arbor

Organisation

Zurich Heart House
Foundation for Cardiovascular Research
Moussonstrasse 4, CH-8091 Zurich, Switzerland
Phone +41 (0) 44 250 40 83, Fax +41 (0) 44 250 40 90 
Esther Willi (esther.willi@usz.ch)

Ruth Amstein, Ph.D.
Kathrin Reber
Valérie Streichenberg

Distinguished international faculty will present lectures, interactive programmes and debates.

Programme Directors

Thomas F. Lüscher, Zurich, CH
Bertram Pitt, Ann Arbor MI, USA

Scientific Coordinator

Ruth Amstein, Zurich, CH

Programme Committee

Ruth Amstein, Ph.D., Zurich, CH
Jeroen J. Bax, M.D., Leiden, NL
Paolo G. Camici, M.D., Milan, IT
Filippo Crea, M.D., Rome, IT
Thierry C. Gillebert, M.D., Gent, BE
John J.P. Kastelein, M.D., Amsterdam, NL
Michel Komajda, M.D., Paris, FR
Thomas F. Lüscher, M.D., Zurich, CH
Bernhard Meier, M.D., Berne, CH
Bertram Pitt, M.D., Ann Arbor, MI, USA
Karl Swedberg, M.D., Gothenburg, SE
William Wijns, M.D., Ph.D., Aalst, BE
Salim Yusuf, M.D., Hamilton, Ontario, CA

Local Programme Committee

Corinna Brunckhorst, M.D., Zurich, CH
Roberto Corti, M.D., Zurich, CH
Firat Duru, M.D., Zurich, CH
Volkmar Falk, M.D., Zurich, CH
Matthias Greutmann, M.D., Zurich, CH
Johannes Holzmeister, M.D., Zurich, CH
Philipp A. Kaufmann, M.D., Zurich, CH
Ulf Landmesser, M.D., Zurich, CH
Willibald Maier, M.D., Zurich, CH
Christian Matter, M.D., Zurich, CH
Georg Noll, M.D., Zurich, CH
Frank Ruschitzka, M.D., Zurich, CH
Christian Schmied, M.D., Zurich, CH
Rudolf Speich, M.D., Zurich, CH
Felix C. Tanner, M.D., Zurich, CH